Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Phase: PHASE2
Conditions: Major Depressive Disorder
Sponsor: Naurex, Inc, an affiliate of Allergan plc

NCT02192099 
 
 
Study ID: GLYX13‐C‐203 
 
 
 
Title: Open Label Extension for Subjects with Inadequate/Partial Response to Antidepressants during the 
Current Episode of Major Depressive Disorder Previously Treated with Rapastinel (GLYX‐13) (Extension 
of GLYX13‐C‐202, NCT01684163) 
 
Protocol Amendment 3 Date: 23 Nov 2016 
 
 
 

Clinical Study Protocol
Protocol Number:
GLYX13-C-203
Study Drug:
Rapastinel (GLYX-13) Injection (rapastinel Injection)
FDA ID:
107,974
Clinicaltrials.gov:
Title:
Open Label Extension for Subjects with Inadequate/Partial 
Response to Antidepressants during the Current Episode of 
Major Depressive Disorder Previously Treated with Rapastinel 
(GLYX-13) (Extension of GLYX13-C-202, NCT01684163)
Study Phase:
2
Sponsor:
Naurex, Inc, an affiliate of Allergan, plc.
Date:
Amendment 3 dated 23 November 2016
Replaces Amendment 2 dated 20 January 2015
This document is a confidential communication from Naurex, Inc, an affiliate of Allergan, plc.. 
Acceptance of this document constitutes an agreement by the recipient(s) that no information 
contained herein will be published or disclosed without prior written approval from Allergan, plc., except 
that this document may be disclosed to appropriate Institutional Review Boards (IRBs) under the 
condition that they are also required to maintain confidentiality.

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 2 of 50
INVESTIGATOR SIGNATURE PAGE
The signature of the investigator below constitutes his/her approval of this protocol and provides 
the necessary assurances that this study will be conducted according to all stipulations of the 
protocol as specified in both the clinical and administrative sections, including all statements 
regarding confidentiality.  This trial will be conducted in compliance with the protocol and all 
applicable regulatory requirements, in accordance with Good Clinical Practices (GCPs), 
including International Conference on Harmonization (ICH) Guidelines, and in general 
conformity with the most recent version of the Declaration of Helsinki.
Principal Investigator
Printed Name
Signature
Date

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 3 of 50
1
SYNOPSIS
Name of Sponsor Company
Naurex, Inc, an affiliate of 
Allergan, plc.
Name of Finished Product
Rapastinel (GLYX-13)
Name of Active Ingredient
Open Label Extension for Subjects with Inadequate/Partial Response to Antidepressants during the 
Current Episode of Major Depressive Disorder Previously Treated with Rapastinel (GLYX-13) (Extension 
of GLYX13-C-202, NCT01684163)
Study No:  GLYX13-C-203
Planned Number of Investigational Sites: 10 US sites
Clinical Phase: Phase 2
Objectives
Primary Objective: 
The primary objective of this study is to examine the safety of long term repeat exposure to rapastinel 
(GLYX-13) in subjects who participated in GLYX13-C-202.
The primary endpoint is the number of participants who experience an adverse event over the course of 
the study.
Methodology:
Study Design:
Phase 2 open label safety study of rapastinel (GLYX-13) for participants who completed 12 weeks of 
treatment in GLYX13-C-202 (NCT01684163).
At the screening visit, the Structured Clinical Interview for Depression (SCID) will be administered to
determine whether any exclusionary conditions have arisen since subject’s completion of GLYX13-C-202.  
  A physical examination will be conducted to ascertain if significant 
changes have occurred since the subject ended participation in GLYX13-C-202.  Blood and urine 
samples will be obtained for laboratory analysis.  Antidepressant agents used since the subject ended 
participation in GLYX13-C-202 will be recorded.
On Week 1 Day 1, subjects will arrive at the investigative site having fasted for at least 10 hours, with 
water as desired.  Each subject’s eligibility will be confirmed; then a physical examination will be 
performed, and blood and urine samples for laboratory analysis will be obtained.  Vital signs will be 
assessed and mass recorded. ECG will be recorded, the 
, 
.  Each subject will then receive an IV dose of 
rapastinel (GLYX-13) (225 mg or 450 mg unit dose) in a “slow bolus” injection in an upper extremity vein 
within approximately 1 to 2 minutes.  Subjects will be discharged following determination by the 
investigator that they are medically able to leave.
Subjects will return to the study site during the first month on the schedule (weekly or biweekly) to which 
they were assigned in GLYX13-C-202.  After the first month subjects will return to the study site on a 

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 4 of 50
Name of Sponsor Company
Naurex, Inc, an affiliate of 
Allergan, plc.
Name of Finished Product
Rapastinel (GLYX-13)
Name of Active Ingredient
L-threonyl-L-prolyl-L-prolyl-L-
threonine amide, acetate salt
schedule defined by treatment plan set by the investigator.
 
 
  Rapastinel (GLYX-13) will be administered.  Subjects will remain in the study unit until
determination by the investigator that they are medically able to leave the study unit.
At the last visit of each quarter, the 
 
 ECG will be recorded and blood and urine samples will be 
obtained for laboratory analysis. Rapastinel (GLYX-13) will be administered.  Subjects will remain in the 
study unit until determination by the investigator that they are medically able to leave.
Dose Level
Unit doses of rapastinel (GLYX-13), 225 mg/3 mL or 450 mg/3 mL IV, will be administered in a “slow 
bolus” injection to each subject in an upper extremity vein within approximately 1 to 2 minutes.
Investigator will begin treatment based on the dose level (5 mg/kg or 10 mg/kg) to which the subject was 
assigned during participation in GLYX13-C-202; subjects originally assigned to 5 mg/kg will receive 225 
mg/3 mL, and subjects originally assigned to 10 mg/kg will receive 450 mg/3 mL.  If subject experiences 
adverse event(s) that the investigator believes may be associated with rapastinel (GLYX-13), the 
investigator may decrease dose level from 450 mg to 225 mg.  If at any point the patient cannot tolerate 
the minimum 225 mg unit dose, the patient should be discontinued from the study.
Dose Interval
Dose interval for the first month of participation will be that (weekly or biweekly) to which the subject was 
assigned during the randomized withdrawal phase of GLYX13-C-202.  The investigator will then formulate 
a treatment plan in which dose interval will remain the same or change.  The treatment plan may be 
modified from time to time by the investigator if it is deemed prudent based on subject’s depression 
status.   
Treatment Plan
Following one month at the dose level (subjects who were assigned to placebo during the randomized 
withdrawal phase of GLYX13-C-202 are eligible to participate and will begin at the dose level to which the 
subject was assigned during the stabilization phase of GLYX13-C-202) and dose interval to which the 
subject was assigned during the randomized withdrawal period of GLYX13-C-202, the investigator may 
continue the same dose level and dose interval, or may change the dose level and dose interval.  The 
investigator will complete a treatment plan that outlines the dose level and dose interval at which 
rapastinel (GLYX-13) will be administered.  The investigator, at the investigator’s discretion, may change 
the treatment plan to alter dose level and/or dose interval based on the subject’s depression status.
Subject Participation:
Participation in the study may continue until rapastinel (GLYX-13) is approved for marketing in the U.S. or 
until the study is ended by the Sponsor.
Number of Subjects Planned 
It is planned to enroll up to 100 subjects who participated in clinical study GLYX13-C-202.
Diagnosis and Main Criteria for Inclusion
Inclusion Criteria:
1.
Participants who have completed 8 or more weeks of treatment in the preceding study 
(GLYX13-C-202, NCT01684163
2.
Participants who wish to continue treatment with rapastinel (GLYX-13) after the 

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 5 of 50
Name of Sponsor Company
Naurex, Inc, an affiliate of 
Allergan, plc.
Name of Finished Product
Rapastinel (GLYX-13)
Name of Active Ingredient
L-threonyl-L-prolyl-L-prolyl-L-
threonine amide, acetate salt
preceding study
3.
Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) 
criteria for major depressive disorder (MDD)
4.
Female subjects of childbearing potential with a negative serum pregnancy test prior to 
entry into the study and who are practicing an adequate method of birth control (eg oral 
or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan 
to become pregnant during the course of the study. Female subjects may be included 
without a negative serum pregnancy test if they are surgically sterile or at least 2 years 
post-menopausal.
5.
Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not 
clinically significant per the investigator and medical monitor
6.
Ability to understand the requirements of the study, provide written informed consent, 
abide by the study restrictions, and agree to return for the required assessments
7.
Based on the investigator and medical monitor’s clinical judgment, subjects with eating 
disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress 
disorder (PTSD), and generalized anxiety disorders secondary to major depressive 
episodes (MDEs) are permitted.
Exclusion Criteria:  
1.
Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, 
schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder 
(anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute 
stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder 
(ADHD), or PTSD
2.
A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, 
schizoid, schizotypal, or histrionic personality disorder
3.
Experiencing hallucinations, delusions, or any psychotic symptomatology in the current 
episode; lifetime history of psychosis
4.
Huntington’s, Parkinson’s, Alzheimer’s, Multiple Sclerosis, or a history of seizures or 
strokes
5.
Currently hospitalized or residing in an in-patient facility during study participation
6.
Substance abuse since the end of participation in GLYX13-C-202, including greater than 
or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, 
or 1 oz. of spirits consumed most weeks or in the opinion of the investigator
7.
Women who are planning to become pregnant during the course of the study
8.
Allergy or intolerance to current antidepressant or other current medications
9.
Participation in any clinical trial of an investigational product or device within 30 days of 
enrollment in this trial with the exception of GLYX13-C-202.
10. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other 
agent that in the opinion of the investigator is being abused
11. Pose current (past 6 months) suicide risk based on administration of the C-SSRS and the 
investigator’s clinical judgment
12. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 
antibody screen) or other ongoing infectious disease

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 6 of 50
Name of Sponsor Company
Naurex, Inc, an affiliate of 
Allergan, plc.
Name of Finished Product
Rapastinel (GLYX-13)
Name of Active Ingredient
L-threonyl-L-prolyl-L-prolyl-L-
threonine amide, acetate salt
Test Product: rapastinel (GLYX-13) (150 mg/mL in water for injection)
Dose and Mode of Dosing:
IV Dosage:
•
225 mg dose in 3 mL with rapastinel concentration 75 mg/mL
•
450 mg dose in 3 mL with rapastinel concentration 150 mg/mL
Study drug will be administered in a “slow bolus” injection to each subject in an upper extremity vein 
within approximately 1 – 2 minutes.
Duration of Dosing: 
Each subject will receive doses of rapastinel (GLYX-13) until ending participation in the study or until 
GLYX-13 is approved for marketing in the U.S.
Criteria for Evaluation:
Safety


All reported AEs

 
Statistical Methods and Data Analysis
Descriptive statistics will be presented for all efficacy and safety parameters. No inferential statistical 
analyses will be performed.
All safety parameters will be summarized for the Safety Population, defined as all subjects who received 
any injection of study drug.
Efficacy parameters will be summarized  for the full analysis set (FAS), defined as all subjects who received any 
injection of study drug and who have at least one post-baseline efficacy assessment. 

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 7 of 50

Naurex, Inc, an affiliate of Allergan, plc.
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 8 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 9 of 50
2
TABLE OF CONTENTS
1
SYNOPSIS.........................................................................................................................3
2
TABLE OF CONTENTS.....................................................................................................9
3
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ............................................12
4
INTRODUCTION..............................................................................................................14
5
STUDY OBJECTIVES......................................................................................................16
5.1
Primary Objective ....................................................................................................16
6
STUDY DESIGN ..............................................................................................................16
6.1
Overall Study Design...............................................................................................16
6.2
Dose Level ..............................................................................................................17
6.3
Treatment Plan........................................................................................................17
6.4
Duration of Subject Participation..............................................................................17
7
SELECTION OF STUDY POPULATION..........................................................................18
7.1
Inclusion Criteria......................................................................................................18
7.2
Exclusion Criteria.....................................................................................................18
7.2.1
Adequate  methods of  birth control ...................................................................19
7.2.2
Permitted Concomitant Treatment .....................................................................19
7.2.3
Recording of Prior/Concomitant Therapy ...........................................................20
8
STUDY DRUGS ...............................................................................................................20
8.1
Study Drug Storage Conditions................................................................................20
8.2
Method of Assigning Subjects to Treatment Groups ................................................20
8.3
Study Drug Dosing...................................................................................................20
8.3.1
Blinding..............................................................................................................21
8.4
Dose Interval ...........................................................................................................21
8.5
Receipt of Supplies..................................................................................................21
8.6
Study Drug Accountability........................................................................................22
8.7
Study Drug Handling and Return .............................................................................22
9
STUDY ASSESSMENTS AND PROCEDURES...............................................................22
9.1
Standardization of Data Capture..............................................................................22
9.2.7
Total Blood Collection Volume ...........................................................................26
10
SUBJECT AND STUDY DISCONTINUATION.................................................................26
10.1
Screen Failures .......................................................................................................26
10.2
Discontinuation from Study......................................................................................27
10.3
Site Discontinuation.................................................................................................27

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 10 of 50
12
SAFETY ASSESSMENTS ...............................................................................................29
12.7
Adverse Events .......................................................................................................30
12.7.1
Recording of Adverse Events.............................................................................30
12.7.2
Severity of Adverse Events................................................................................30
12.7.3
Relationship Assessment...................................................................................31
12.7.4
Action Taken......................................................................................................32
12.7.5
Outcome............................................................................................................32
12.8
Serious Adverse Events...........................................................................................32
13
DATA MANAGEMENT ....................................................................................................34
14
STATISTICS ....................................................................................................................35
14.1
General Considerations ...........................................................................................35
14.2
Study Populations....................................................................................................35
14.3
Efficacy Analyses.....................................................................................................35
14.4
Sample Size Determination .....................................................................................36
15
ADMINISTRATIVE ASPECTS .........................................................................................37
15.1
Compliance with Regulatory Requirements .............................................................37
15.2
Institutional Review Board Approval ........................................................................37
15.3
Informed Consent ....................................................................................................38
15.4
Confidentiality..........................................................................................................38
15.5
Compensation, Insurance and Indemnity.................................................................39
15.6
Protocol Amendment ...............................................................................................39
15.7
Case Report Forms .................................................................................................39
15.8
Source Document Maintenance...............................................................................39
15.9
Study Monitoring Requirements...............................................................................39
15.10
Study File Management...........................................................................................40
15.11
Study Completion ....................................................................................................40
15.12
Audits ......................................................................................................................40
15.13
Retention of Records...............................................................................................40
15.14
Disclosure of Data ...................................................................................................40
15.15
Financial Disclosure.................................................................................................41
15.16
Publication Policy.....................................................................................................41

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 11 of 50
16
REFERENCES.................................................................................................................42
17
APPENDICES..................................................................................................................43
In-Text Tables
Table 2
Dose Volumes for Dosing ..................................................................................21

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 12 of 50
3
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
ADT
Antidepressant treatment
ADHD
Attention-Deficit Hyperactivity Disorder
AE
adverse event
ATC
Anatomical Therapeutic Chemical Classification
CRF
case report form
CRO
Clinical Research Organization
CTCAE
Common Terminology Criteria for Adverse Events
DMID
Division of Microbiology and Infectious Diseases
DSM-IV-TR
Diagnostic and Statistical Manual, Fourth Edition, Text Revision
ECG
Electrocardiogram
eCRF
electronic case report form
FDA
Food and Drug Administration
GCP
Good Clinical Practices
 
HIV
human immunodeficiency virus
ICF
informed consent form
ICH
International Conference on Harmonization
IV
Intravenous
IWRS
interactive web response system
LSMs
least square means
MedDRA
Medical Dictionary for Regulatory Activities
MDD
major depressive disorder
MDEs
major depressive episodes
MTD
maximum tolerated dose
NaCl
sodium chloride
NCI
National Cancer Institute

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 13 of 50
NMDAR
N-methyl-D-aspartate receptor
NR2B
NMDA receptor 2B
PTSD
Post-Traumatic Stress Disorder
QID-SR
Quick Inventory of Depressive Symptomatology Self Report
Q-LES-Q SF
Quality of Life Enjoyment and Satisfaction Questionnaire Short Form
SAE
serious adverse event
SAP
Statistical analysis plan
SCID
Structured Clinical Interview for Diagnostic and Statistical Manual (DSM) of 
Mental Disorders

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 14 of 50
4
INTRODUCTION
The rationale for evaluating rapastinel (GLYX-13) in subjects with treatment-resistant 
depression results from recent studies using ketamine, a N-methyl-D-aspartate receptor 
(NMDAR) channel blocker, and CP-101,606, a competitive NMDAR antagonist.  Both of these 
agents are efficacious in animal models and human diseases in which NMDAR have been 
implicated, but both suffer psychotomimetic effects that render them impractical to use for 
chronic therapy.  When administered as single intravenous (IV) doses to subjects with treatment-
resistant depression, the NMDAR antagonists ketamine 1 (channel blocker) and CP-101,606 2
(NMDA receptor 2B [NR2B] competitive antagonist) induced significant, rapid antidepressant 
effects that lasted for several days following single doses, even though both of these agents, like 
rapastinel (GLYX-13), have short plasma half-lives.  In subjects who received ketamine in a 
crossover study compared to placebo, improvement in depression scores was apparent at first 
assessment (40 minutes following dose); this improvement remained significant throughout the 
following week.  Of 17 subjects treated with ketamine, 71% responded (> 50% reduction in 
depression score) and 29% experienced remission (depression score < 7) by 24 hours.  At 
1 week, 35% of responders maintained response following the single dose.  Psychotomimetic 
effects were apparent at 40 minutes.  
In a study in subjects who had failed paroxetine (the lead-in period of the trial), subjects who 
received a single intravenous (IV) dose of CP-101,606 showed improvement in depression 
scores compared to placebo at Day 5 (primary endpoint).  Of 15 subjects treated with 
CP-101,606, 60% responded, and 33% experienced remission. Of responders, 78%, 58%, 42% 
and 30% maintained response on Days 8, 12, 15, and 30.  Psychotomimetic effects were 
observed in many of the subjects who received CP-101,606.  Thus, single IV doses of ketamine 
or CP-101,606 caused rapid, sustained reductions in depression despite plasma half-lives of 
2 hours.  
These studies are particularly interesting from the perspectives of medical need and commercial
opportunity since the onset of action of existing antidepressant drugs is 2 weeks or longer and 
about one-half of subjects do not achieve a response to the first drug tried.  About 30% of 
subjects do not respond to any of multiple drugs tried.  In contrast, ketamine and CP-101,606 
both produced responses in most subjects, even though all of these subjects had failed at least 
2 other antidepressant drugs.  Further, the onset of antidepressant action was rapid, within hours 
for ketamine.  Either of these effects in a drug that can be used therapeutically (neither ketamine 
nor CP-101,606 can be due to their psychotomimetic side effects) would be an advance in 
therapeutics.
Rapastinel (GLYX-13) is an NMDAR glycine site functional partial agonist.3  IV administration 
of rapastinel (GLYX-13) results in rapid antidepressant-like activity in the Porsolt assay in rats 
without changes in locomotor activity or inhibition of prepulse inhibition that predict 
psychotomimetic side effects in humans.3  In rats and normal human volunteers, rapastinel 
(GLYX-13) exhibits plasma half-life of less than 10 minutes following IV administration.  In a 
phase 2a study (GLYX13-C-201) in subjects with MDD who had failed (< 25% improvement 
using the ATRQ) at least one antidepressant agent during the current episode in whom all 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 15 of 50
antidepressant agents had been washed out for 14 days, a single IV dose of rapastinel (GLYX-
13), 5 mg/kg or 10 mg/kg, reduced 
 compared to placebo within one day and activity 
lasted for 7 days, but not 14 days.7  Psychotomimetic side effects assessed using the BPRS+ 
scale were not observed in any subjects.
This protocol will now explore fixed IV doses of 225 mg (to replace 5 mg/kg) and 450 mg (to 
replace 10 mg/kg).  In previous studies, rapastinel (GLYX-13) has been studied at dose levels up 
to 30 mg/kg IV and was found to be well tolerated.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 16 of 50
5
STUDY OBJECTIVES
5.1
Primary Objective
The primary objective of this study is to examine the safety of long term repeat exposure to 
rapastinel (GLYX-13) in subjects who participated in GLYX13-C-202.
The primary endpoint of this study is to examine the number of participants who experience an 
adverse event over the course of the study.
6
STUDY DESIGN
6.1
Overall Study Design 
This is a phase 2 open label safety study of GLYX-13 for participants who completed 12 weeks 
of treatment in GLYX13-C-202 (NCT01684163).
At the screening visit, the Structured Clinical Interview for Depression (SCID) will be 
administered to determine whether any exclusionary conditions have arisen since subject’s 
completion of GLYX13-C-202.  
.  A physical examination will be 
conducted to ascertain if significant changes have occurred since the subject ended participation 
in GLYX13-C-202.  Blood and urine samples will be obtained for laboratory analysis.  
Antidepressant agents used since the subject ended participation in GLYX13-C-202 will be 
recorded.
On Week 1, subjects will arrive at the investigative site having fasted for at least 10 hours, with 
water as desired.  Each subject’s eligibility will be confirmed; then a physical examination will 
be performed, and blood and urine samples for laboratory analysis will be obtained.  Vital signs 
will be assessed and mass recorded.  ECG will be recorded, 
 
.  Each subject will 
then receive an IV dose of rapastinel (GLYX-13), 225 mg or 450 mg (replaces 5 mg/kg or 10 
mg/kg, respectively) in a “slow bolus” injection in an upper extremity vein within approximately 
1 to 2 minutes.  Subjects will be discharged following determination by the investigator that they 
are medically able to leave.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 17 of 50
Subjects will return to the study site during the first month on the schedule (weekly or biweekly) 
to which they were assigned in GLYX13-C-202.  After the first month subjects will return to the 
study site on a schedule defined by treatment plan set by the investigator.  
 
 Rapastinel (GLYX-13) will be administered.  Subjects will 
remain in the study unit until determination by the investigator that they are medically able to 
leave the study unit.
 
.  ECG will be recorded and blood 
and urine samples will be obtained for laboratory analysis. Rapastinel (GLYX-13) will be 
administered.  Subjects will remain in the study unit until determination by the investigator that 
they are medically able to leave.
6.2
Dose Level
Unit doses of rapastinel (GLYX-13), 225 mg/3 mL or 450 mg/3 mL IV, will be administered in a 
“slow bolus” injection to each subject in an upper extremity vein within approximately 1 to 2 
minutes. Investigator will begin treatment based on  the dose level (5 mg/kg or 10 mg/kg) to 
which the subject was assigned during participation in GLYX13-C-202; subjects originally 
assigned to 5 mg/kg will receive 225 mg/3 mL, and subjects originally assigned to 10 mg/kg will 
receive 450 mg/3 mL.  If subject experiences adverse event(s) that the investigator believes may 
be associated with rapastinel (GLYX-13), the investigator may decrease dose level from 450 mg 
to 225 mg.  If at any point the patient cannot tolerate the minimum 225 mg unit dose, the patient 
should be discontinued from the study.
6.3
Treatment Plan
Following one month at the dose level (subjects who were assigned to placebo during the 
randomized withdrawal phase of GLYX13-C-202 are eligible to participate and will begin at the 
dose level to which the subject was assigned during the stabilization phase of GLYX13-C-202) 
and dose interval to which the subject was assigned during the randomized withdrawal period of 
GLYX13-C-202, the investigator may continue the same dose level and dose interval, or may 
change the dose level and dose interval.  The investigator will complete a treatment plan that 
outlines the dose level and dose interval at which rapastinel (GLYX-13) will be administered.  
The investigator, at the investigator’s discretion, may change the treatment plan to alter dose 
level and/or dose interval based on the subject’s depression status.
6.4
Duration of Subject Participation 
Each subject will receive rapastinel (GLYX-13) until rapastinel (GLYX-13) is approved for 
marketing by the U.S. FDA or until the subject discontinues from the study, or until the Sponsor 
stops the study.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 18 of 50
7
SELECTION OF STUDY POPULATION 
7.1
Inclusion Criteria
The subject must meet the following criteria to be eligible for enrollment into this study:
1.
Participants who have completed 8 or more weeks of treatment in the preceding study 
(GLYX13-C-202, NCT01684163
2.
Participants who wish to continue treatment with rapastinel (GLYX-13) after the preceding 
study
3.
Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) 
criteria for major depressive disorder (MDD)
4.
Female subjects of childbearing potential with a negative serum pregnancy test prior to 
entry into the study and who are practicing an adequate method of birth control (eg oral or 
parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to 
become pregnant during the course of the study. Female subjects may be included without 
a negative serum pregnancy test if they are surgically sterile or at least 2 years post-
menopausal.
5.
Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not 
clinically significant per the investigator and medical monitor
6.
Ability to understand the requirements of the study, provide written informed consent, 
abide by the study restrictions, and agree to return for the required assessments
7.
Based on the investigator and medical monitor’s clinical judgment, subjects with eating 
disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress 
disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes 
(MDEs) are permitted.
7.2
Exclusion Criteria 
The subject will not be eligible for enrollment if any of the following criteria are met:
1. Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, 
schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia 
or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, 
agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD
2. A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, 
schizotypal, or histrionic personality disorder
3. Experiencing hallucinations, delusions, or any psychotic symptomatology in the current 
episode; lifetime history of psychosis

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 19 of 50
4. Huntington’s, Parkinson’s, Alzheimer’s, Multiple Sclerosis, or a history of seizures or 
strokes
5. Currently hospitalized or residing in an in-patient facility during study participation
6. Substance abuse since the end of participation in GLYX13-C-202, including greater than or 
equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 
oz. of spirits consumed most weeks or in the opinion of the investigator
7. Women who are planning to become pregnant during the course of the study
8. Allergy or intolerance to current antidepressant or other current medications
9. Participation in any clinical trial of an investigational product or device within 30 days of 
enrollment in this trial with the exception of GLYX13-C-202.
10. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent 
that in the opinion of the investigator is being abused
11. Pose current (past 6 months) suicide risk based on administration of the C SSRS and the 
investigator’s clinical judgment 
12. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 
antibody screen) or other ongoing infectious disease
7.2.1
Adequate  methods of  birth control
Over the course of the study, females of childbearing potential must practice a method of 
contraception with greater than 90% reliability. Women of childbearing potential are women 
who are not 2 years postmenopausal, or not surgically sterile.  Typical acceptable forms of 
birth control are:
•
cervical cap with spermicide
•
diaphragm with spermicide
•
male condom
•
oral contraceptives
•
intrauterine devices
•
medroxyprogesterone acetate
•
levonorgestrel subdermal implants
•    abstinence
7.2.2
Permitted Concomitant Treatment
Subjects may use any drug not specifically excluded in the exclusion criteria.
During the study, subjects will be reminded to abstain from alcohol and not to use illegal drugs 
or prescription drugs not prescribed by a doctor.
Cough syrup with dextromethorphan cannot be used within 2 weeks before the baseline visit and 
cannot be used during the study.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 20 of 50
7.2.3
Recording of Prior/Concomitant Therapy
All antidepressant drugs and other drugs taken during the current depressive episode to within 30 
days of Screening will be carefully documented.  During the study, subjects will report permitted 
concomitant drugs taken to the site study personnel during each study visit. 
8
STUDY DRUGS
Rapastinel (GLYX-13) 450 mg IV Prefilled Syringes: 
 
 
Rapastinel (GLYX-13) 225 mg IV Prefilled Syringes: 
 
 
.
8.1
Study Drug Storage Conditions 
Study drug must be stored refrigerated 
  
Drug supplies will be kept in an appropriate secure area and stored in accordance with 
specifications on the drug labels.  Site will maintain shipment records from the depot and ensure 
supplies are received under the proper conditions.  A drug inventory record of supplied, received, 
dispensed, and returned study drug must be maintained by the pharmacy representative on an 
ongoing basis.  The investigator is required to return unopened kits of study drug to the Sponsor 
at the end of the trial (Sponsor will provide specific instructions). The pharmacy representative
is required to maintain copies of study drug shipping receipts, drug accountability records, and 
records of return or final disposal of study drug.  This form must be available at all times for 
inspection by the medical monitor or field monitor.
8.2
Method of Assigning Subjects to Treatment Groups
Subjects will be assigned initially to the dose level and frequency to which they were assigned 
during the randomized withdrawal portion of clinical study GLYX13-C-202.  Following one 
month of participation, dose level and dose frequency may be changed by the investigator 
according to a treatment plan formulated by the investigator at the investigator’s discretion.
8.3
Study Drug Dosing
Study drug will only be administered to eligible subjects under the supervision of the investigator 
or identified subinvestigator(s) or other assigned personnel licensed to administer IV drugs.  

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 21 of 50
Table 2
Dose Volumes for Dosing
Dose Level
mg IV
Dose Volume
(mL/subject)
This replaces
225 
3.0
5 mg/kg
450
3.0
10 mg/kg
Study drug (rapastinel [GLYX-13]) will be administered using a syringe attached to a butterfly 
catheter in a “slow bolus” to an upper extremity vein to each study subject within approximately 
1 to 2 minutes.  
8.3.1
Blinding
This is an open label safety study.
8.4
Dose Interval
Dose interval for the first month of participation will be that (weekly or biweekly) to which the 
subject was assigned during the randomized withdrawal phase of GLYX13-C-202.  The 
investigator will then formulate a treatment plan in which dose interval will remain the same or 
change.  The treatment plan may be modified from time to time by the investigator if it is 
deemed prudent based on subject’s depression status.   
8.5
Receipt of Supplies
Upon receipt of the investigational drug, the pharmacist or designee will visually inspect the 
shipment and verify the drug information, quantity, and condition of the study drug received.    
The pharmacist will complete the accompanying Temptale form by following the instructions on 
the form.
The study drug will be supplied in kits, each containing 1 prefilled syringe, a plunger, and a 
needle, and labeled with the protocol number, kit number, contents, lot number, storage 
information, Sponsor, warning language (“Caution: New Drug—Limited by Federal Law to 
Investigational Use. Keep Out of Reach of Children”), and instructions for use to refer to 
protocol, as well as fields for the patient identification (PID) number, patient initials, study 
center number, visit number, and date dispensed to be recorded. The study center will write on 
both panels the patient’s PID number and patient’s initials along with the study center number, 
visit number, and date dispensed.
The study center personnel will complete the kit label and attach the tear-off portion to the 
source documents.  
The prefilled syringe will be labeled with the protocol number and kit number. The study center 
personnel will write the PID number on the prefilled syringe associated with the kit mentioned 
above.  The prefilled syringe will not have a tear off and will remain on the prefilled syringe. .

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 22 of 50
8.6
Study Drug Accountability 
The Sponsor will provide the investigator with sufficient amounts of the study drug to begin the 
study.  It is the responsibility of the investigator to ensure that a current record of inventory/study 
drug accountability is maintained.  Inventory records must be readily available for inspection by 
the study monitor during the study and are open to inspection by regulatory authorities at any 
time.  
Pharmacy personnel or other designated site staff will account for, store and dispense the study 
drug.  At the end of the study, all study drug must be accounted for. In addition, at the end of the 
study, all unused study drug should be returned to the Sponsor or the local distributor at the 
address provided in the SSARF (Study Specific Accountability Return Form).   
8.7
Study Drug Handling and Return
The study drug must be stored refrigerated 
 
. Sites must report any temperature excursions as described in the Study Reference Manual 
or contact the Sponsor or its designee for further instructions.
Upon completion or termination of the study, all unused kits of study drug will be returned to the 
Sponsor’s representative.   The site will dispose of any used study drug as part of the site internal 
SOP for disposing of sharps and biohazard material. Instructions for return of unused study drug 
will be supplied near completion of the study.
9
STUDY ASSESSMENTS AND PROCEDURES 
9.1
Standardization of Data Capture
Dosing of study drug to subjects in this study will be performed by a qualified designee under 
the supervision of a licensed health care provider listed on the FDA Form 1572.  Accurate, 
consistent, and reliable data will be ensured by using standard practices and procedures presented 
by the sponsor and applicable regulatory authorities.
 
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 23 of 50
 
 
 
  
 
  
  

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 24 of 50
 
 
 
  
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 25 of 50
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 26 of 50
 
9.2.7
Total Blood Collection Volume
The total volume of blood collected over each year of participation will be less than 100 mL.
10
SUBJECT AND STUDY DISCONTINUATION
10.1
Screen Failures
Subjects who sign and date the informed consent form (ICF) but who fail to meet the inclusion 
and exclusion criteria are considered screen failures.  A screening log, which documents the 
subject initials and reason(s) for screen failure, is to be maintained by the investigator for all 
screen failures.  A copy of the log should be retained in the investigator’s study files. Subjects 
may be rescreened on a case-by-case basis upon discussion between the investigator and the 
Medical Monitor.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 27 of 50
10.2
Discontinuation from Study 
A subject may be prematurely discontinued from the study for any of the following reasons:

Adverse event

Withdrew consent

Physician decision

Pregnancy

Protocol deviation

Lost to follow-up

Site terminated by Sponsor

Study terminated by Sponsor

Other
10.3
Site Discontinuation
Reasons for discontinuation of the study may include, but are not limited to, the following:

The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to subjects.

Subject enrollment is unsatisfactory.

Investigator request to withdraw from participation.

Sponsor decision.

Serious and/or persistent non-compliance by the investigator with the protocol, the 
clinical research agreement, the Form FDA 1572 or applicable regulatory guidelines in 
conducting the study.

Institutional review board (IRB) decision to terminate or suspend approval for the 
investigation or the investigator.

Investigator fraud (altered data, omitted data, or manufactured data).

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 28 of 50
11
EFFICACY ASSESSMENTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 29 of 50
 
 
 
 
12
SAFETY ASSESSMENTS 
 
 
 
 
 
 
  
  
 
 
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 30 of 50
12.7
Adverse Events
Subjects should be queried in a non-leading manner, without specific prompting (eg, “How are 
you feeling?”).  The site study staff should assess emerging symptoms of dissociative reaction 
similar to those caused by other NMDA antagonists including memory impairment, disturbance 
in time, body or environmental perception, stilted speech, emotional withdrawal, impaired 
coordination, motor retardation, bizarre reasoning or illusory experiences in any sensory 
perception, or confused state; such symptoms may be captured as adverse events.  
An “adverse event” is any untoward, undesired, unplanned clinical event in the form of signs, 
symptoms, disease, or laboratory or physiological observations occurring in a human being 
participating in a clinical study with an investigational product, regardless of causal relationship.  
A “pre-existing” condition is one that is present before study drug dosing and is reported as part 
of the subject’s medical history.  Pre-existing conditions should be reported as an AE only if the 
frequency, intensity, or character of the pre-existing condition worsens during the course of the 
study.
Laboratory abnormalities are not considered AEs unless they are associated with clinical signs or 
symptoms, or require medical intervention.  However, a laboratory abnormality (eg, a clinically 
significant change detected on clinical chemistry, coagulation, hematology, urinalysis) that is 
independent from the underlying medical condition and that requires medical or surgical 
intervention, or leads to study drug interruption or discontinuation, must be considered an AE. 
12.7.1
Recording of Adverse Events
Subjects should be instructed to report all AEs to the investigator.
AE collection begins at 
signing of ICF and ends 30 days after last dosing injection.  In addition, the investigator should 
seek to elicit any clinical or objective reactions by specific questioning (eg, “How have you been 
feeling?”) and, as appropriate, by examination.  Information on all AEs should be recorded on 
the eCRF.  All clearly related signs, symptoms, and results of diagnostic procedures performed 
because of an AE should be grouped together and recorded as a single diagnosis.  The 
component parts of the diagnosis may be listed for verification.  If the AE is a laboratory 
abnormality that is part of a clinical condition or syndrome, it should be recorded as the 
syndrome or diagnosis rather than the individual laboratory abnormality.
To avoid vague, ambiguous, or colloquial expressions, all AEs should be recorded in standard 
medical terminology on the eCRF and on the medical record rather than in the subject’s own 
words.  Each AE will also be described in terms of duration (start and stop date), severity, 
association with the study drug, action(s) taken, and outcome. 
12.7.2
Severity of Adverse Events
All AEs will be assessed for severity, using the following general grading scale:
GRADE 1
Mild:  Transient or mild discomfort (< 48 hours); no medical 
intervention/therapy required.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 31 of 50
GRADE 2
Moderate: Mild to moderate limitation in activity - some assistance may 
be needed; no or minimal medical intervention/therapy required.
GRADE 3
Severe: Marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization possible.
GRADE 4
Life-threatening: Extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization 
or hospice care probable.
Severity grades for specific safety parameters will be assigned according to the National Institute 
of Allergy and Infectious Diseases, DMID Adult Toxicity Table (Modified) in Appendix I.  For 
AEs involving a body system or laboratory value not included in the DMID table, the National 
Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 
(2009) will be used.  When changes in the severity of an AE occur more frequently than once a 
day, the maximum severity for the experience that day should be noted.  If the severity category 
changes over a number of days, then those changes should be recorded separately (with distinct 
onset dates).
12.7.3
Relationship Assessment 
For each reported AE, the investigator must assess the relationship of the event to the study drug
using the following scale:
Unrelated

Does not follow a known response pattern to the suspect study drug (if response 
pattern is previously known).

Can clearly be explained by the known characteristics of the subject’s clinical state or 
other modes of therapy administered to the subject.
Unlikely Related

The temporal sequence from dosing of the study drug suggests that a relationship is 
unlikely.

Follows a response pattern that is unlike that of the suspect study drug (if response 
pattern is previously known).

Could be reasonably explained by the subject’s clinical state or other modes of 
therapy administered to the subject.
Possibly Related

Follows a reasonable temporal sequence from dosing of the study drug. 

May follow a known response pattern to the suspect study drug (if response pattern is 
previously known).

Could also be reasonably explained by the subject’s clinical state or other modes of 
therapy administered to the subject.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 32 of 50
Probably Related

Follows a reasonable temporal sequence from dosing of the study drug. 

Could not be reasonably explained by the known characteristics of the subject’s 
clinical state or any other modes of therapy administered to the subject.

Is confirmed by improvement on stopping or slowing dosing of the study drug, if 
applicable.
When an assessment is not provided, the event will be treated as Possibly Related for purposes of 
regulatory reporting.
12.7.4
Action Taken 
For each reported AE, the investigator must document the action taken according to the 
following criteria:

No action taken

Non-pharmacologic treatment added

New drug therapy added

Discontinued from study

New or prolonged hospitalization
12.7.5
Outcome
For each reported AE, the investigator must document the outcome according to the following 
criteria:

Recovered

Ongoing

Unknown

Death
12.8
Serious Adverse Events
An SAE is any AE occurring at any dose that results in any of the following outcomes:

Death 
“Death” is an outcome and is NOT the AE.  In the event of death, the cause of death 
should be recorded as the AE.  The only exception is “sudden death” when the cause 
is unknown.

Is a life-threatening experience 
Life-threatening AEs include any adverse drug experience, which, in the view of the 
investigator, places the subject at immediate risk of death from the reaction as it 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 33 of 50
occurs.  It does not include a reaction that, had it occurred in a more serious form, 
might have caused death.

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in a persistent or significant disability/incapacity  
Disability is defined as a substantial disruption in a person’s ability to conduct normal 
life functions.

Results in a congenital anomaly/ birth defect

Additionally, important medical events that may not result in death, be life-threatening, 
or require hospitalization may be considered an SAE when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above.  Example: allergic 
bronchospasm requiring intensive treatment in an emergency room or at home.
All SAEs that result in death or are life-threatening, regardless of causal relationship, must be 
reported to the medical monitor within 24 hours of the site’s knowledge of the event.  A copy of 
the initial SAE report must be received within one (1) business day.
All other SAEs or other events reportable to FDA and/or IRB will be forwarded to the medical 
monitor within one (1) business day.
The SAE report should provide as much of the required information as is available at the time.  
The following minimum information is required for reporting an SAE:  subject identification, 
reporting source, and an event outcome.  Supplemental information may be transmitted using a 
follow-up report and should not delay the initial report.  The Sponsor will contact the 
investigational site to solicit additional information or to follow up on the event.
If there is any doubt whether the information constitutes an SAE, the information will be treated 
as an SAE for the purposes of this protocol. Serious adverse event collection will begin after 
signing the ICF and end 30 days after the last dose.  
Serious adverse events will be followed until resolution or return to baseline (when worsening of 
a pre-existing condition is reported).
All relevant documentation pertaining to the SAE (additional laboratory tests, consultation 
reports, discharge summaries, postmortem reports, etc.) will be provided by the investigator to 
the medical monitor in a timely manner.
 
 
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 34 of 50
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13
DATA MANAGEMENT 
Study data will be entered into eCRFs. Before data analysis, programmed edit checks will be run 
against the database to check for discrepancies and reasonableness of the data. All issues 
resulting from the computer-generated checks will be resolved.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 35 of 50
14
STATISTICS
14.1
General Considerations
Quantitative assessments will be summarized using descriptive statistics including the mean,
standard deviation, median, minimum and maximum values.  Changes from baseline will be 
summarized where appropriate.  
Qualitative assessments will be reported as frequencies and percents within each assessment 
level.  Unless specified otherwise, the denominator for percents will the number of subjects in 
each treatment group.  Shift tables may be produced for some assessments and will contain 
counts of subjects in each cross-classification level of baseline versus post-baseline assessment 
without percents.  Only subjects with a baseline will be included in these tables but a missing 
category will be permitted for post-baseline values.
The baseline value for a given assessment will be the last non-missing observation collected 
before administration of study drug.  
14.2
Study Populations
Subject disposition, demographics, and baseline assessments will be summarized using all 
enrolled subjects, whether or not the study drug was received.
The safety population will consist of all subjects who received any injection of study drug.  All 
safety summaries will be based on this population.
The full analysis set (FAS) will consist of all subjects who received any injection of study drug 
and who have at least one post-baseline efficacy assessment.  All efficacy summaries and 
analyses will be produced using this population and it will be considered the primary efficacy 
population.
 
l 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 36 of 50
14.4
Sample Size Determination
This study is open to subjects who participated in clinical study GLYX13-C-202 at specified 
investigative sites.  Up to 100 subjects are eligible.
 
 
 
 
 
 
 
 
 
 
 
 
  
 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 37 of 50
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
14.6
Pharmacokinetic Analysis
No pharmacokinetics samples will be obtained during this study.
15
ADMINISTRATIVE ASPECTS
15.1
Compliance with Regulatory Requirements
This protocol will be conducted in compliance with the protocol and all regulatory requirements, 
in accordance with Good Clinical Practices (GCP), including International Conference on 
Harmonization (ICH) Guidelines, and in general conformity with the most recent version of the 
Declaration of Helsinki.
15.2
Institutional Review Board Approval
This protocol, the informed consent document, and all relevant supporting data must be 
submitted to the IRB for approval.  IRB approval of the protocol, informed consent document, 
and any advertisement used to recruit study subjects must be obtained before the study may be 
initiated.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 38 of 50
The principal investigator is responsible for keeping the IRB advised of the progress of the study 
and of any changes made to the protocol as deemed appropriate, but in any case, at least once a 
year.  The principal investigator is also responsible for notifying the IRB of any significant AEs 
that occur during the study.
The Sponsor will submit all protocol related documents for approval by the IRB for those sites 
able to use a central IRB.
15.3
Informed Consent
It is the policy of the Sponsor that written informed consent is obtained from subjects.  The 
informed consent document must be signed and dated before the initiation of non-routine study-
related tests, and before dosing of study drug.  The original signed ICF for each participating 
subject shall be filed with records kept by the investigators(s).  A copy of the informed consent 
document must be provided to the subject.  If applicable, it will be provided in a certified 
translation of the local language. HIPAA requirements will be included in the ICF. 
The subject’s Bill of Rights will be included in the Informed Consent process in sites located in 
California. 
15.4
Confidentiality
Personal study subject data collected and processed for the purposes of this study should be 
managed by the investigator and his/her staff with adequate precautions to ensure the 
confidentiality of those data, and in accordance with applicable national and/or local laws and 
regulations on personal data protection.
Monitors, auditors, and other authorized agents of the Sponsor, the IRB approving this research, 
and applicable regulatory authorities will be granted direct access to the study subjects’ original 
medical records for verification of clinical study procedures and/or data, without violating the 
confidentiality of the subjects, to the extent permitted by the law and regulations.  In any 
presentation of the results of this study at meetings or in publications, the subjects’ identity will 
remain confidential.   

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 39 of 50
15.5
Compensation, Insurance and Indemnity
Information regarding compensation, insurance, and indemnity is addressed in the Clinical Trial 
Research Agreement.
15.6
Protocol Amendment
If a protocol has been filed with regulatory agencies or submitted to an IRB and requires 
changes, a protocol amendment must be written.  Any changes to the protocol will be made by 
the sponsor.  All amendments will be sent to the IRB on the study sites’ behalf. Sites using a 
local IRB are then responsible for submitting the amendment to their local IRB for approval.
15.7
Case Report Forms
An electronic CRF (eCRF) will be used to record all subject data specified by this protocol.  The 
eCRF must be completed by designated and trained study personnel within 72 hours of the study 
visit.  The eCRF will be signed by the principal investigator or a subinvestigator listed on the 
FDA Form 1572.  It is the responsibility of the principal investigator to ensure the CRFs are 
completed and submitted to the Sponsor (or designee) in an accurate and timely manner.  The 
processing of eCRFs will include an audit trail (to include changes made, reason for change, date 
of change and person making change).  
15.8
Source Document Maintenance
Source documents are defined as the results of original observations and activities of a clinical 
investigation.  Source documents may include, but are not limited to, study progress notes, 
e-mail correspondences, computer printouts, laboratory data, and drug accountability records.  
All source documents produced in this study will be maintained by the Investigator(s) and made 
available for inspection by Sponsor representatives, the FDA and any other applicable regulatory 
authorities.
15.9
Study Monitoring Requirements
Site visits will be conducted by an authorized Sponsor representative (the monitor) to inspect 
study data, subject’s medical records, and CRFs in accordance with ICH guidelines, GCPs, and 
the respective US or national regulations and guidelines, as applicable.  It will be the monitor’s 
responsibility to inspect the CRFs at regular intervals throughout the study, to verify the 
adherence to the protocol and the completeness, consistency and accuracy of the data being 
entered.  The monitor should have access to laboratory test reports and other subject records 
needed to verify the entries on the CRFs.
The Investigator will permit staff and contracted representatives of the Sponsor, the FDA, and/or 
respective health authorities to inspect facilities and records relevant to this study.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 40 of 50
15.10
Study File Management
It will be the responsibility of the investigator(s) to assure that the study file at the site is 
maintained.  The study file will contain, but will not be limited to, source documents, CRFs, and 
all other administrative documents, eg, IRB correspondence, clinical trial materials and supplies 
shipment manifests, monitoring logs, Sponsor correspondence, and so forth.  A study-specific 
binder will be provided with instructions for the maintenance of study records.
15.11
Study Completion
The Sponsor requires the following data and materials before a study can be considered complete 
or terminated: source documents, completed, and signed CRFs.
15.12
Audits
During the course of the study, or after completion of the study, each study site may be subject to 
an audit by a Quality Assurance Auditor (or an auditor appointed by the Sponsor or its 
authorized representative) and/or an inspector from the FDA and/or other regulatory authority.  
Every attempt will be made to notify the Investigator in writing in advance of the audit. 
15.13
Retention of Records
According to US Investigational New Drug (IND) regulations (21 CFR 312.62), records and 
documents pertaining to the conduct of this study and the distribution of study drugs including 
CRFs, ICFs, laboratory test results, and drug inventory records will be retained.  These records 
will be kept on file by the principal investigator for 2 years after a marketing application is 
approved for the drug for the indication for which it is being studied.  If no application is filed or 
approved, these records must be kept for 2 years after the investigation has been discontinued 
and the FDA has been notified.  Per ICH guidelines, documents should be retained until at least 2 
years after the last approval of a marketing application in an ICH region and until there are no 
pending or contemplated marketing applications in an ICH region, or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational product.  
The Sponsor will notify the investigator when records and documents no longer need to be 
retained.  No study records should be destroyed without prior written authorization from the 
Sponsor.
15.14
Disclosure of Data
The investigator agrees by his/her participation that the results of this study may be used for 
submission to national and/or international registration and supervising authorities.  If required, 
these authorities will be provided with the names of investigators, their addresses, qualifications 
and extent of involvement.  It is understood that the Investigator is required to provide the 
Sponsor with all study data, complete reports, and access to all study records.  
Data generated by this study must be available for inspection by the FDA and other regulatory 
authorities, by the Sponsor, and the IRB as appropriate.  At a subject’s request, medical 
information may be given to his or her personal physician or other appropriate medical personnel 

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 41 of 50
responsible for his or her welfare.  Subject medical information obtained during the course of 
this study is confidential and disclosure to third parties other than those noted above is 
prohibited.
15.15
Financial Disclosure
The FDA Financial Disclosure by Clinical Investigators (21 CFR 54) regulations require 
sponsors to obtain certain financial information from investigators participating in covered 
clinical studies; each principal investigator and subinvestigator is required to provide the 
required financial information and to promptly update the Sponsor with any relevant changes to 
their financial information throughout the course of the clinical study and for up to 1 year after 
its completion.  This rule applies to all investigator(s) and subinvestigator(s) participating in 
covered clinical studies to be submitted to the FDA in support of an application for market 
approval.
15.16
Publication Policy
The publication policy is outlined in the Clinical Trial Agreement.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 42 of 50
16
REFERENCES 
1. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney 
DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-
resistant major depression. Arch Gen Psychiatry 2006; 63:856-864.
2. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative 
design to establish proof of concept of the antidepressant effects of the NR2B subunit 
selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-
refractory major depressive disorder. J Clin Psychopharmacol 2008; 28:631-637.
3.  Moskal JR, Kuo AG, Weiss C, Wood PL, O’Connor S, Hanson A, Kelso S, Harris RB, 
Disterhoft JF.  2005.  Neuropharmacology 49: 1077-1087.
4. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 
56-62.
5. Guy W. editor.  ECDEU Assessment Manual for Psychopharmacology. 1976. Rockville 
MD, U.S. Department of Health, Education, and Welfare.
6. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. (2007). Columbia 
Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal 
Events in the FDA’s Pediatric Suicidal Risk Analysis of Antidepressants. American 
Journal of Psychiatry 2007, 164(7): 1035-1043.
7.  Moskal JR, Burch RM, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD.  
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition 
and produces antidepressant side effects without the psychotomimetic side effects of 
NMDA receptor antagonists.  Expert Opin Investig Drugs 23:  243-254.

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 43 of 50
17
APPENDICES

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 44 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 45 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 46 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 47 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 48 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 49 of 50

Naurex, Inc, an affiliate of Allergan, plc
Protocol GLYX13-C-203
Amendment 3  23 November 2016
Confidential
Page 50 of 50